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Introduction
Nowadays, modern clinical outcomes and cost-effectiveness 
issues mandate careful attention to the process flow 
governing the diagnostic and therapeutic pathways in lung 
cancer management (1). Best practice protocols, like Proven 
Care, are characterized by the focus on the diagnostic and 
therapeutic value of surgery as the central modality in 
managing early as well as locally advanced NSCLC (1). 
Indeed, surgery has been considered for decades the ideal 
therapeutic option mainly to ensure optimal local control 
of the disease. The aim of this paper is to demonstrate that 
minimally invasive thoracic surgery (MITS) remains the 
best management choice for early NSCLC because, besides 
continuing to warrant best local control, it is crucial to 
provide tissue for biomolecular studies and effect the best 
pathological staging while preserving lung parenchyma (2,3).
Local control
One of the advantages of surgical treatment for early stage 
NSCLC includes local control of the disease. Recurrent 
tumors may be present at different sites after initial surgery. 
In this setting, and unlike many of the series based on other 
modalities of local control of NSCLC, the surgical series 
are characterized by a precise definition of the concept of 
local recurrence (1). In case of local recurrence, tumors may 
involve adjacent lung parenchyma, the bronchial stump, 
or the hilum adjacent to the bronchial stump (4). Regional 
failure means that recurrence is located in the hilum 
separate from the bronchial stump, mediastinum, chest 
wall or the ipsilateral pleura (4). When distant failure is 
present, tumor occurs in the separate lobe of the ipsilateral 
lung, contralateral thorax, supraclavicular lymph nodes 
or in a distant organ (4). According to ACOSOG Z0030 
trial conducted among 578 pT1 and 440 pT2 patients with 
recurrent early stage NSCLC, the median overall survival 
(OS) for pT1 tumors was 9.1 years and 6.5 years for pT2, 
respectively (4). The 5-year disease free survival was 77% 
for pT1 and 58% for pT2, respectively whereas the 5-year 
local disease-free survival was 95% for pT1 and 91% for 
pT2, respectively (4). When the patterns of recurrence 
were considered, local recurrence was observed in 1% 
and 3% of T1 and T2 tumors, respectively (4). Moreover, 
regional and combined local and regional recurrences 
were seen in 4% and 0.4% for T1, and, 3% and 0.7% 
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for T2 subsets, respectively (4). Conversely, randomized 
trials of stereotactic body radiation treatment like RTOG 
0236 do not generally provide a detailed breakdown of the 
recurrence sites and fail, at this point in time, to prospect 
5 year survival figures (4). The fact that stereotactic body 
radiotherapy (SBRT) remains a promising modality for 
local control of NSCLC is demonstrated by the 91% 
and 87% 3-year local and loco-regional recurrence free 
survival rates observed in RTOG 0236 (4). Even in large 
retrospective series, the local and regional recurrence rates 
at 2 years after SBRT were 4.9% and 7.8%, respectively (5). 
In the same study from the Netherlands, the corresponding 
local and regional recurrence rates after 5 years were 10.5% 
and 12.7%, respectively (5). The difference in local and 
regional relapse compared to the results from ACOSOG 
Z0030 trial is particularly significant if one considers that 
65% (441 patients out of 676) in the SBRT retrospective 
study did not have a pre-treatment histological diagnosis 
of lung cancer (5). A direct comparison of the available 
treatment modalities to attain local control of early stage 
lung cancer was published by the MD Anderson Cancer 
Center in 2012 (6). Overall, more than 10,000 patients 
with stage I NSCLC older than 66 years (median age, 
75 years) were considered (6). Among the possible 
treatment options, lobectomy, sublobar resection, SBRT, 
conventional radiation, and, observation were evaluated and 
the main conclusion was that lobectomy yielded the best 
overall and disease-specific survival rate after 6 months (6). 
A caveat to the interpretation of the results was suggested 
by the limited number of SBRT patients in a retrospective 
series which were nevertheless analyzed with the propensity 
score method (6). However, SBRT was related to the best 
mortality rate within 6 months of treatment (6).
Tissue for biomolecular evaluation
One of the most intriguing perspectives of biomolecular 
medicine is the possibility of diagnosing lung cancer on 
blood samples (7,8). Recently, Sozzi and coworkers in the 
MILD lung cancer screening trial have demonstrated that 
combining screening with low dose CT (LDCT) scan and 
miRNA signatures the rate of false positives can be reduced 
fivefold, thus limiting the resort to unnecessary surgery (9). 
Theoretically, blood-based diagnosis would facilitate 
targeted treatment especially in patients with lung cancer 
relapses or convey reluctant or inoperable patients towards 
non-surgical therapies with the certainty of a histological 
type. However, the recent reports of increasing resistance 
to targeted drugs emphasize the concept of multiclonality 
within the same tumor mass (10). Accordingly, only 
representative samples from a tumor mass could ensure 
adequate genomic profiling in the perspective of targeted 
treatment. The role of surgical biopsies in this context 
seems obvious especially if tumor resistance is to be 
ascertained and avoided. Likewise, the question arises as 
to whether circulating tumor cells or DNA can replace the 
diagnostic accuracy of surgical specimens in the future (11). 
In this setting, next generation sequencing (NGS) 
platforms can be applied to circulating cells as well as free 
DNA and are already showing promising results (12). 
However, since most mutations in tumor DNA do not 
contribute to oncogenesis and are transient, the clinical 
impact of NGS platforms is yet to be understood (12). 
Sizeable samples may still be necessary in order to 
distinguish driver from transient mutation (12). In the 
meantime, costs and disadvantages of NGS platforms 
represent the hurdles to be overcome for a more widespread 
use of this technology (12).
In this setting, the detection of areas in the airways prone 
to develop recurrences in close contiguity to resected lung 
parenchyma or after definite time frames from previous 
pulmonary resection is intriguing because biomolecular 
studies seem to show the potential to orient the clinical 
surveillance by analyzing modulation of genetic expression 
in the bronchial epithelium (13).
Correct staging
Adequate patient selection is crucial to obtain long-term 
results when any local modality of lung cancer treatment is 
used. In this context, correct clinical and pathological staging 
represents a tenet of modern thoracic surgery. Guidelines 
have proposed to effect standardized protocols for both 
preoperative and intraoperative staging (14). The quest for 
the identification of subsets of mediastinal nodal involvement 
amenable to primary surgery has provided important practical 
consequences (15). As an example, in Europe, occult as well as 
single station N2 NSCLC are now increasingly considered a 
surgical disease given the encouraging survival rates reported 
in surgical series (15). Minimally invasive techniques, 
especially VATS, enable surgeons to solve clinical dilemmas 
with staging procedures which can be performed under 
locoregional anesthesia (3,16,17). Operations effected via 
single port (uniportal) VATS are used to distinguish between 
T2 and T3 or N2 and N3 when EBUS and mediastinoscopy 
are not helpful or cannot be technically carried out. In the 
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setting of prethoracotomy exploration of the mediastinum, 
video assisted mediastinal lymphadenectomy (VAMLA) 
and trascervical extended mediastinal lymphadenectomy 
(TEMLA) represent another example of single port surgery 
which can be used to better select surgical candidates for 
lung resection (18,19). The whole staging-based prognostic 
infrastructure of oncologic treatment modalities is the 
guiding principle for the selection of surgery for early stage 
lung cancer (20). Without histological confirmation, only 
clinical stages can be compared between treatment yielding 
an apparent outcome equipoise (21); this is particularly 
relevant if one thinks that regional failures after SBRT may 
account to 15% and mediastinal failures can be found in 7.5% 
of the patients originally treated with ablative radiation (22). 
To further complicate this issue, it has been reported that 
histological confirmation of lung cancer patients treated with 
SBRT is needed in only 35% of the patient population (5). 
To justify this paradigm shift not yet supported by 
conventional collected evidence (i.e., prospective, randomized 
trials-see above), a theoretical pathway leading to SBRT-led 
treatment of early stage lung cancer has been put forward 
which includes ad hoc interpretation of current guidelines, 
PET driven decision analysis, extremely conservative estimate 
of patients’ preoperative cardio-respiratory reserve or the 
adoption of somewhat vague and unconventional terminology 
(i.e., pulmonary insufficiency) when defining operability, 
and the accidental inattention to thoracic surgical input into 
tumor boards (5,23,24). However, the quality issues in SBRT 
administration are partially counterbalanced by similar pitfalls 
of surgical treatment. Indeed, advocates of SBRT emphasize 
the non homogeneous quality of surgery outside clinical 
trials, especially in terms of intraoperative nodal sampling or 
dissection (25). The thoracic surgical community is taking 
action and a more rigorous attitude towards mediastinal 
lymphadenectomy is currently advised (26). 
The meaning of minimally invasive thoracic 
surgery (MITS)
As surgeons, we are concerned with offering the best possible 
procedure to our patients in order to obtain the longest 
recurrence free survival (27). In this context, sublobar 
resections are under scrutiny for their oncologic efficacy 
compared to SBRT as an alternative to lobectomy for early 
stage lung cancer (28,29). In particular, wedge resection 
have been considered by some authors a sort of palliative 
surgical procedure which should be replaced by anatomical 
segmentectomy with nodal dissection as the procedure of 
choice for stage IA NSCLC (27). Again, a matter of quality 
in surgery has been raised, with regard to the tumor-free 
margins attainable during non-anatomical segmentectomy, i.e., 
lung wedge resection (27). Be as it may, correct indications 
for wedge resection still remain and include CT screened 
small, subcentimetric nodules and ground glass opacities 
(GGOs) especially when the solid component is less than 25% 
compared to the ground glass counterpart (30). In addition, 
authoritative institutions have reported no differences in 
survival between sublobar (including wedge resections) and 
lobectomy for solid nodules classified as clinical stage IA 
NSCLC (31). 
Conclusions
One shared statement that depicts the current surgical 
philosophy towards lung cancer is expressed in the recent 
Society of Thoracic Surgeons’ recommendations on the 
role of surgeons in the lung CT screening programs (30). 
Modern surgery for early stage lung cancer needs to focus 
on “the least parenchymal resection compatible with current 
diagnostic and oncologic principles performed through the 
least invasive surgical approach” (30). By respecting this 
fundamental principle, surgery remains in 2014 the best 
management option for early stage lung cancer. 
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